Risdiplam is the sole orally administered drug approved for your treatment method of SMA. It was FDA approved in 2020 for use in individuals two months of age and older, and it features as an SMN2 gene splicing modifier leading to greater amounts of SMN protein. Oral administration is an https://helena074rxa8.blogunteer.com/profile